Evidence map›Paper›PMID 39073669›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2024

Characterization of a colistin resistant, hypervirulent hospital isolate of Acinetobacter courvalinii from Canada.

Ellen M E Sykes, Valeria Mateo-Estrada, Anna Muzaleva, George Zhanel, Jeremy Dettman, Julie Chapados, Suzanne Gerdis, Ömer Akineden, Santiago Castillo-Ramírez, Izhar U H Khan and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Draft genome sequence of anMicrobiology resource announcements · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ellen M E SykesDepartment of Microbiology, University of Manitoba Winnipeg, Winnipeg, MB, R3T 2N2, Canada.
Valeria Mateo-EstradaPrograma de Genómica Evolutiva, Centro de Ciencias Génomicas, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Anna MuzalevaDepartment of Microbiology, University of Manitoba Winnipeg, Winnipeg, MB, R3T 2N2, Canada.
George ZhanelDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Canada.
Jeremy DettmanOttawa Research and Development Centre (ORDC), Agriculture and Agri-Food Canada, Ottawa, Canada.
Julie ChapadosOttawa Research and Development Centre (ORDC), Agriculture and Agri-Food Canada, Ottawa, Canada.
Suzanne GerdisOttawa Research and Development Centre (ORDC), Agriculture and Agri-Food Canada, Ottawa, Canada.
Ömer AkinedenDairy Sciences, Institute of Veterinary Food Science, Justus-Liebig-University of Giessen, Giessen, Germany.
Santiago Castillo-RamírezPrograma de Genómica Evolutiva, Centro de Ciencias Génomicas, Universidad Nacional Autónoma de México, Cuernavaca, Mexico.
Izhar U H KhanOttawa Research and Development Centre (ORDC), Agriculture and Agri-Food Canada, Ottawa, Canada.
Ayush KumarDepartment of Microbiology, University of Manitoba Winnipeg, Winnipeg, MB, R3T 2N2, Canada. Ayush.Kumar@umanitoba.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-baumannii Acinetobacter spp. are becoming more prevalent in clinical settings including those that present resistance to last-resort antibiotics such as colistin. AB222-IK40 is an Acinetobacter courvalinii strain isolated from the Ottawa Hospital Research Institute located in Ottawa, Canada. To our knowledge, it is the first report of clinical A. courvalinii in Canada. Based on the susceptibility profile, AB222-IK40 is resistant to colistin and non-susceptible to ertapenem. Whole-genome sequencing allowed for genomic investigation into colistin resistance mechanisms. No previously identified mechanism(s) were observed, but a mobile colistin resistance (mcr)-like gene and a UDP-glucose dehydrogenase gene were identified. Based on phylogenomic analyses, the mcr-like gene is an intrinsic phosphoethanolamine transferase. This gene family is implicated in one of the many mechanisms responsible for colistin resistance in Acinetobacter baumannii as well as Acinetobacter modestus. UDP-glucose dehydrogenase is involved in colistin resistance in Enterobacterales and has been shown to be involved in capsule formation in A. baumannii. Global lipidomics revealed greater abundance of phosphatidyl-myo-inositol and lyso-phosphatidyl ethanolamine moieties in the membrane of A. courvalinii than in A. baumannii. Lipidomic profiles showed differences that were probably responsible for the colistin resistance phenotype in AB222-IK40. This isolate was also hypervirulent based on survival assays in Galleria mellonella. As this is the first report of A. courvalinii from a hospital in Canada, this species may be an emerging clinical pathogen, and therefore, it is important to understand this mechanism of its colistin resistance and hypervirulence.

Indexed as

AcinetobacterAcinetobacter InfectionsAnti-Bacterial AgentsColistinDrug Resistance, BacterialMicrobial Sensitivity TestsAnimalsCanadaHumansPhylogenyVirulenceWhole Genome SequencingAnti-Bacterial AgentsColistinColistin resistanceEmerging pathogenHypervirulent clinical Acinetobacter courvaliniiLipidomics

Identifiers

PMID39073669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.